



**BlueCross
BlueShield**

Federal Employee Program.

Blue Cross Blue Shield Association
750 9th St NW, Suite 900
Washington, D.C. 20001
1-800-624-5060
Fax 1-877-378-4727

5.30.055

Section:	Prescription Drugs	Effective Date:	July 1, 2026
Subsection:	Endocrine and Metabolic Drugs	Original Policy Date:	June 29, 2018
Subject:	Palynziq	Page:	1 of 5

Last Review Date: June 11, 2026

Palynziq

Description

Palynziq (pegvaliase-pqpz)

Background

Palynziq (pegvaliase-pqpz) is a phenylalanine (Phe)-metabolizing enzyme indicated to reduce blood phenylalanine concentrations in patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L. Prolonged high blood phenylalanine levels are neurotoxic and lead to impairment of intelligence and other brain functions, such as attentiveness. Reduction of blood Phe levels through dietary control is an important determinant of long-term neurologic outcome in phenylketonuria (PKU) patients, and reduction of blood Phe levels in patients with PKU has been shown to decrease the long-term risk of neurologic injury. Palynziq substitutes for the deficient phenylalanine hydroxylase (PAH) enzyme activity in patients with PKU and reduces blood phenylalanine concentrations (1).

Regulatory Status

FDA-approved indication: Palynziq is a phenylalanine (Phe)-metabolizing enzyme indicated to reduce blood phenylalanine concentrations in adult and pediatric patients 12 years of age and older with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management (1).

Palynziq has a boxed warning that anaphylaxis may occur at any time during Palynziq treatment (1).

Administration of the initiation dose of Palynziq must be under the supervision of a healthcare provider equipped to manage anaphylaxis, and patients must be closely observed for at least 60

Section:	Prescription Drugs	Effective Date:	July 1, 2026
Subsection:	Endocrine and Metabolic Drugs	Original Policy Date:	June 29, 2018
Subject:	Palynziq	Page:	2 of 5

minutes following injection. Prior to self-administration, confirm patient competency with self-administration, and patient's and observer's (if applicable) ability to recognize signs and symptoms of anaphylaxis and to administer auto-injectable epinephrine, if needed (1).

The prescriber should prescribe an auto-injectable epinephrine and provide instructions on its appropriate use. The patient should be advised to carry the epinephrine injector at all times while on Palynziq and if used, to seek follow up medical care (1).

Palynziq is available only through a restricted program called the Palynziq REMS Program (1).

The safety and effectiveness of Palynziq in pediatric patients less than 12 years of age have not been established (1).

Related policies

Kuvan

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Palynziq may be considered **medically necessary** if the conditions indicated below are met.

Palynziq may be considered **investigational** for all other indications.

Prior-Approval Requirements

Age 12 years of age and older

Diagnosis

Patient must have the following:

Phenylketonuria (PKU)

AND ALL of the following:

1. Blood phenylalanine concentration > 600 micromol/L after a trial of sapropterin dihydrochloride (Kuvan)

Section:	Prescription Drugs	Effective Date:	July 1, 2026
Subsection:	Endocrine and Metabolic Drugs	Original Policy Date:	June 29, 2018
Subject:	Palynziq	Page:	3 of 5

2. Physician agrees to assess patient tolerability, blood phenylalanine concentration, and dietary protein and phenylalanine intake throughout treatment
3. Prescriber and patient must be enrolled with the Palynziq REMS Program
4. Auto-injectable epinephrine has been prescribed and the patient or caregiver has been instructed in its use
5. **NOT** to be used in combination with Kuvan/Javygtor (sapropterin) or Sephience (sepiapterin)

Prior-Approval *Renewal* Requirements

Age 12 years of age and older

Diagnosis

Patient must have the following:

Phenylketonuria (PKU)

1. Auto-injectable epinephrine has been prescribed and the patient or caregiver has been instructed in its use
2. Patient had adequate response to treatment
3. **NOT** to be used in combination with Kuvan/Javygtor (sapropterin) or Sephience (sepiapterin)

[Policy Guidelines](#)

Pre-PA Allowance

None

Prior-Approval Limits

Duration 6 months

Prior-Approval *Renewal* Limits

Duration 12 months

Section:	Prescription Drugs	Effective Date:	July 1, 2026
Subsection:	Endocrine and Metabolic Drugs	Original Policy Date:	June 29, 2018
Subject:	Palynziq	Page:	4 of 5

Rationale

Summary

Palynziq (pegvaliase-pqpz) is a phenylalanine-metabolizing enzyme indicated to reduce blood phenylalanine concentrations in patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L. Palynziq substitutes for the deficient phenylalanine hydroxylase (PAH) enzyme activity in patients with PKU and reduces blood phenylalanine concentrations. The safety and effectiveness of Palynziq in pediatric patients less than 12 years of age have not been established (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Palynziq while maintaining optimal therapeutic outcomes.

References

1. Palynziq [package insert]. Novato, CA. BioMarin Pharmaceutical, Inc.; February 2026.

Policy History

Date	Action
June 2018	Addition to PA
September 2018	Annual review Addition of auto-injectable epinephrine requirements and trial of Kuvan per SME
December 2019	Annual review
October 2020	Removal of renewal requirement that patient needed to have at least 20% reduction in phenylalanine concentration from baseline or reduction in phenylalanine concentration to ≤ 600 micromol/L Addition of renewal requirement that patient must have adequate response to treatment
December 2020	Annual review
September 2021	Annual review and reference update
September 2022	Annual review
September 2023	Annual review
March 2024	Annual review
March 2025	Annual review
March 2026	Annual review and reference update

5.30.055

Section:	Prescription Drugs	Effective Date:	July 1, 2026
Subsection:	Endocrine and Metabolic Drugs	Original Policy Date:	June 29, 2018
Subject:	Palynziq	Page:	5 of 5

April 2026	Per PI update, lowered age limit to 12 years of age and older. Added no dual therapy with Sephience
June 2026	Annual review

[Keywords](#)

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on June 11, 2026 and is effective on July 1, 2026.